Castle biosciences stock.
Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued.The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to Buy Now Castle Biosciences, Inc. (NASDAQ ...
Oct 31, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ... Nov 16, 2023 · Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...
Nov 24, 2023 · Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. 2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...Dec 1, 2023 · In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media. Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 -4.19% -0.60 Home CSTL •...
What is the target price for Castle Biosciences (CSTL) stock? The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set ...
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...
Secrets and treasures of the ancient world are scattered all across the globe. One of the most incredible discoveries in the history of exploring the ancient world was recently unearthed completely by accident.Dec 1, 2023 · In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media. Castle Biosciences today announced it has signed a definitive agreement to acquire Cernostics, Inc. ... which may consist entirely of cash or $20 million in cash and $10 million in common stock of ...View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Dec 1, 2023 · View Castle Biosciences, Inc CSTL investment & stock information. Get the latest Castle Biosciences, Inc CSTL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...
Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 6.59% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $17.08 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to date ...Mar 20, 2023 · Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholders Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …
3 Haz 2023 ... The company's shares closed yesterday at $22.73. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Repligen, and ...In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...
Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... Are you yearning for adventure, breathtaking landscapes, and a journey through history? Look no further than a tour of Scotland and Ireland. These two countries boast rich cultural heritage, stunning natural beauty, and countless attraction...In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...On average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64.In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...S hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ...A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ...
Oct 25, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...
Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MA high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Track Castle Biosciences Inc (CSTL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences to Participate in Upcoming Investor Conferences. FRIENDSWOOD, Texas-- (BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle …The all-time high Castle Biosciences stock closing price was 97.33 on February 09, 2021. The Castle Biosciences 52-week high stock price is 29.59, which is 64.4% above the current share price. The Castle Biosciences 52-week low stock price is 9.26, which is 48.6% below the current share price. The average Castle Biosciences stock price for the ...Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
Are you yearning for adventure, breathtaking landscapes, and a journey through history? Look no further than a tour of Scotland and Ireland. These two countries boast rich cultural heritage, stunning natural beauty, and countless attraction...Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Which Castle Biosciences insiders have been selling company stock? The following insiders have sold CSTL shares in the last 24 months: Daniel Bradbury ($6,274,776.69), and Derek J Maetzold ($1,265,588.97).The estimated Net Worth of Bernhard E. Spiess is at least $7.14 Million dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $346,275 and over the last 4 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.Instagram:https://instagram. how much is the john f kennedy coin worthvgt stock forecastforesight financialvalue of gold bar Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.The estimated net worth of David S. Kabakoff is at least $3.83 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $3,831,935 as of November 6th. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net … luckin coffe stockhow to buy stock in nvidia November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ... 10 best stocks to buy Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...Castle Biosciences Inc (CSTL) Stock Expected to Experience Positive Growth on November 3, 2023: Analysts Predictions and Ratings. On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median …The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86.During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35.The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. Volume has …